Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
LUVOX CR is an extended-release oral capsule formulation of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) approved in 2008. The mechanism of action involves inhibition of serotonin reuptake in the central nervous system. Indication-specific data is not provided, but SSRIs are commonly used for obsessive-compulsive disorder, depression, and anxiety disorders.
With LOE approaching and moderate competitive pressure (30% intensity), brand team focus is likely shifting toward lifecycle defense and cost optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero currently linked job openings and LOE approaching, LUVOX CR offers limited career growth opportunities; positions tied to this product typically focus on defending market share and managing the transition to generic competition. Career professionals should expect eventual transition to Jazz's growth-stage portfolio or competitive products.
Worked on LUVOX CR at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.